How Long Does Sublocade Last in Your System?

Sublocade, the monthly buprenorphine injection used to treat opioid use disorder, releases medication slowly over roughly four to five weeks after each shot, but traces of buprenorphine can remain detectable in the body for considerably longer than that. After your final injection, the drug does not simply vanish on day 30. The solid depot that forms under the skin continues to dissolve for months, keeping plasma levels above therapeutic thresholds for weeks and producing measurable drug levels for longer still. Understanding exactly how this timeline plays out matters for anyone planning to stop treatment, switch medications, undergo surgery, or manage pain.

How the Depot Releases Buprenorphine

Unlike a sublingual buprenorphine film or tablet that you take daily, Sublocade is designed as an in situ forming implant. The injection is a clear solution of buprenorphine fully dissolved in a polymer system. Once the liquid is injected under the skin of your abdomen, it contacts body fluids and solidifies into a small, firm depot about the size of a marble. That solid mass then degrades gradually, releasing buprenorphine into your bloodstream at a steady pace over the course of a month.

This delivery method is what makes the drug’s presence in your system so prolonged. The depot does not release all its medication in a neat 30-day window and then disappear. Instead, the polymer continues to break down after the bulk of the drug has been released, and smaller amounts of buprenorphine keep leaking out for weeks beyond the intended dosing interval. After multiple monthly injections, residual depots from earlier months may still be partially dissolving alongside the newest one, which contributes to a buildup of stable drug levels over time.

Clinical data from combined phase II and III trials with 570 participants confirmed that therapeutic buprenorphine concentrations were achieved from the very first injection and were maintained throughout the entire treatment period. After treatment was discontinued, plasma concentrations of buprenorphine decreased slowly rather than dropping off a cliff.¹

What “Lasting in Your System” Actually Means

There are several different ways to think about how long Sublocade stays in your body, and they give very different answers depending on what you care about.

If you are asking how long the drug provides a therapeutic effect, the answer is roughly a month per injection, which is the intended dosing schedule. Pharmacokinetic simulations showed that even a two-week delay between doses would not meaningfully reduce the drug’s efficacy, because buprenorphine levels stay high enough to keep opioid receptors occupied during that gap.¹ That two-week buffer is meaningful for patients who might miss an appointment or have trouble getting to a clinic on time.

If you are asking how long the drug is pharmacologically active after your last injection, the answer stretches well beyond 30 days. Buprenorphine’s own elimination half-life from the depot formulation is estimated to be in the range of 43 to 60 days, depending on how many injections you have received. That means it takes roughly two months for your blood levels to drop by half after the last shot, and several more months before the drug clears entirely. After a standard course of treatment, detectable levels of buprenorphine may persist for two to five months following your final dose.

If you are asking about drug-testing detectability, the window is even wider. Standard immunoassay urine panels do not typically screen for buprenorphine, but specialized tests can detect it and its metabolite norbuprenorphine for months after the last Sublocade injection, particularly if you received multiple doses.

What Happens After Your Last Injection

One of the most common concerns about Sublocade is what withdrawal will feel like once you stop. Because the drug tapers itself out of your system gradually, the experience is considerably different from stopping sublingual buprenorphine cold turkey.

An observational case series studying patients who discontinued long-acting injectable buprenorphine found that withdrawal symptoms were minimal to mild in most cases. The average peak withdrawal score was 4.8 on the Clinical Opioid Withdrawal Scale, which falls squarely in the “mild” category. That peak typically occurred around five to six weeks after the final injection, though for some participants it ranged from four to eight weeks out.²

This built-in self-taper is one of Sublocade’s most distinctive features. With daily sublingual buprenorphine, patients who stop abruptly can experience moderate withdrawal within a day or two. With the depot injection, the slow dissolution of the polymer means blood levels drift downward over weeks, giving the brain time to adjust. Some patients report feeling essentially nothing for the first month after their last shot, with only subtle symptoms appearing weeks later, often so mild they are not sure if it is withdrawal or something else entirely.

That said, “minimal on average” does not mean zero for every person. Some patients in the case series experienced peak symptoms closer to the moderate range, and the psychological component of stopping opioid agonist therapy can be significant even when physical withdrawal is mild. Anxiety about relapse and difficulty sleeping are commonly reported even when the formal withdrawal scores remain low.

Whether a Missed Dose Matters

Because the depot continues to release buprenorphine beyond its 28-day intended window, missing your next appointment by a week or two is unlikely to cause problems. The pharmacokinetic modeling from clinical trials specifically showed that a two-week delay in dosing would not compromise treatment efficacy.¹ This finding was robust enough to be included in the product labeling.

This buffer is practically useful. Life happens: clinics close, weather events disrupt transportation, scheduling conflicts arise. Knowing that a short delay will not send you into withdrawal or leave you unprotected is reassuring. However, the buffer is not unlimited. Delays beyond two weeks start to push into territory where blood levels may dip below the therapeutic range, particularly if you have only received one or two injections. Patients who have been on Sublocade for many months tend to have higher baseline levels due to accumulation from overlapping depots, so they are more resilient to delays than someone who just got their first shot.

How Drug Interactions Affect How Long It Lasts

Buprenorphine is metabolized primarily by the CYP3A4 enzyme system in the liver. Medications that strongly inhibit or rev up that enzyme can change how quickly your body processes the drug, which in turn affects how long effective levels persist.

Modeling studies evaluated what happens when Sublocade is taken alongside strong CYP3A4 inhibitors like ketoconazole and itraconazole. The predicted effect was a mild increase in buprenorphine exposure, on the order of about a third to slightly under half more drug in the bloodstream compared to taking Sublocade alone.³ In the other direction, rifampicin, a strong CYP3A4 inducer, was predicted to decrease buprenorphine exposure by about 28%.³

Separate modeling of a related long-acting buprenorphine formulation reached similar conclusions: a strong inhibitor increased exposure by roughly 34 to 35 percent, and a strong inducer decreased it by about 26 percent. Researchers concluded that no dose adjustment was necessary because the magnitude of these interactions was not clinically meaningful.⁴

The practical takeaway is that common antifungal medications, certain HIV treatments, and a handful of antibiotics can nudge buprenorphine levels up or down, but the changes are modest enough that they should not meaningfully alter how long the drug stays active in your system or require you to change your Sublocade schedule. If you are prescribed a strong enzyme inhibitor or inducer for an extended period, mention your Sublocade to the prescribing doctor, but do not expect a dramatic change in your treatment.

Surgery, Pain Management, and the Long Tail

The prolonged presence of buprenorphine after Sublocade creates a genuine challenge in one specific scenario: acute pain management. Because buprenorphine is a partial opioid agonist with very strong receptor binding, it effectively blocks or blunts the effect of full opioid painkillers like morphine, oxycodone, and fentanyl. If you need surgery or experience a painful injury, the buprenorphine still circulating from your depot can make it harder for doctors to control your pain with standard opioid protocols.

This is not a theoretical concern. Emergency physicians and anesthesiologists are increasingly encountering patients who have a Sublocade depot on board. The standard approach involves using higher doses of full agonist opioids to compete for receptor binding, employing non-opioid pain strategies like regional nerve blocks, ketamine, and anti-inflammatory medications, and working closely with the patient’s addiction medicine team. The key thing patients should know is that the depot cannot be removed or “turned off.” Once it is under your skin, you are committed to having buprenorphine in your system for months. If you have a planned surgery coming up, discuss the timing with both your surgeon and your prescribing provider well in advance.

Pregnancy and Breastfeeding

The long systemic presence of Sublocade raises understandable questions for pregnant or breastfeeding patients. Evidence is still being collected, but early findings are cautiously encouraging.

A review of clinical practice case studies and postmarketing surveillance data examined outcomes from pregnant patients who received monthly buprenorphine depot injections. In four detailed case reports, all neonates were delivered full-term with normal birthweight, no fetal anomalies, and none required medication for neonatal opioid withdrawal syndrome. Over 300 pregnancies had been captured through postmarketing surveillance, and the 68 with known outcomes were consistent with the established safety profile of buprenorphine during pregnancy.⁵

For breastfeeding, a pharmacokinetic study found that buprenorphine appeared in breast milk at low levels among patients receiving extended-release buprenorphine injections, comparable to the levels seen in patients taking daily sublingual buprenorphine. The solvent used in the formulation (NMP) did pass into breast milk but was not detected in infant plasma. Researchers noted that additional data are needed before making definitive recommendations, but the early profile was similar to what is already considered acceptable with sublingual buprenorphine during breastfeeding.⁶

The wrinkle for pregnancy planning is timing. Because Sublocade stays in the body for months after the last injection, a patient who becomes pregnant shortly after their final dose will still have significant buprenorphine exposure during the first trimester. Buprenorphine itself is widely used and accepted during pregnancy, so this is not inherently a problem, but it does mean the decision to use Sublocade versus daily sublingual formulations involves thinking ahead about reproductive plans and the ability to adjust doses if needed. A depot cannot be titrated downward once injected.

Why Some People Stop Early

The extended presence of the drug after injection is one of the things that makes Sublocade effective for treatment adherence, but it is also a source of tension for some patients. Unlike a daily pill or film that you can choose not to take tomorrow, the depot locks you into treatment for at least a month, arguably longer given its slow clearance.

A qualitative study exploring patient motivations for discontinuing depot buprenorphine identified four main reasons: feeling forced into the program, experiencing negative side effects, finding the treatment ineffective, and either wanting to use opioids again or feeling “cured” and no longer needing medication-assisted treatment. Underlying these practical concerns were broader themes around autonomy and bodily control. Some patients felt uncomfortable with a treatment they could not stop or adjust on their own terms.⁷

This dynamic is worth understanding because it cuts both ways. The inability to simply skip a dose is protective against relapse, which is why many clinicians and patients view Sublocade favorably. But that same feature can feel coercive to patients who were pressured into the treatment or who develop side effects they want to escape. Honest conversations between patients and providers about what “committing to a month at a time” actually means, including the extended tail, can help set appropriate expectations before the first injection.

How Sublocade Compares on Cost

The long duration of action and reduced clinic visits might seem like they would make Sublocade cheaper than daily sublingual buprenorphine, but the economics are more complicated than that. The medication itself carries a significantly higher per-dose price than generic sublingual buprenorphine films or tablets.

A U.S.-based economic evaluation found that when compared to transmucosal buprenorphine, extended-release buprenorphine yielded slightly lower overall health outcomes at higher cost, meaning the injectable was “dominated” in health-economics terms and was not the preferred option from a cost-effectiveness standpoint.⁸ A U.K.-based trial found a slightly different picture: the injectable was both more costly and marginally more effective, but at a price per quality-adjusted life year that exceeded what the health system typically considers good value. Among patients with more severe opioid use disorder at baseline, however, the injectable actually dominated standard care, meaning it was both cheaper and more effective for that subgroup.⁹

For patients with insurance that covers Sublocade, the out-of-pocket difference may be negligible. For those navigating coverage gaps or Medicaid formularies, the higher upfront cost can be a real barrier. The manufacturer offers a patient assistance program, but access varies. The point is that the decision to use Sublocade is rarely just about pharmacokinetics; the financial dimension shapes who can realistically access it and for how long.

Starting Sublocade and the Transition Period

Before receiving a first Sublocade injection, patients are typically required to be stabilized on sublingual buprenorphine for at least seven days. In one implementation trial, participants spent a minimum of seven days on 8 to 32 mg of daily sublingual buprenorphine before transitioning to monthly depot injections.¹⁰ This lead-in period serves two purposes: it confirms the patient tolerates buprenorphine well at an appropriate dose, and it ensures they are not in active withdrawal or at risk of precipitated withdrawal when the depot begins releasing medication.

Once the first injection is given, therapeutic blood levels are achieved quickly rather than requiring weeks to build up. This is a meaningful advantage over some other long-acting medications that take multiple doses to reach steady state. However, the first month or two often involve the most variability in how patients feel, because the depot is still establishing its release pattern and residual levels from earlier injections have not yet accumulated. By the third or fourth injection, blood levels tend to be more stable and predictable, and the protective buffer against missed doses grows stronger.